OBJECTIVES: This study was undertaken to evaluate whether the adoption of the united network for organ sharing lung allocation score (LAS) was associated with significant changes in lung transplantation (LTX) outcomes for patients with interstitial lung disease (ILD) who underwent LTX at the University of Wisconsin Hospital and Clinics.
INTRODUCTION
Interstitial lung disease (ILD) encompasses a large and heterogeneous group of diffuse parenchymal lung diseases [1, 2] . These subacute or chronic conditions can lead to respiratory insufficiency and death in a significant number of patients, especially for patients with a diagnosis of idiopathic pulmonary fibrosis (IPF). Epidemiologic studies have shown an appreciable incidence and prevalence of ILD, and IPF was a highly prevalent form of ILD vs. other forms of ILD [3] . Currently, available pharmacologic therapies may not arrest the disease process, especially for patients with IPF, and progressive respiratory failure and death will eventually occur [1, 4] . The high failure rate of currently available treatments for advanced lung disease due to ILD makes alternative therapeutic options a necessity.
Lung transplantation (LTX) represents a therapeutic option for selected patients with severe ILD refractory to medical therapy that can potentially improve both the quality of life and survival [5] . According to the latest data from the International Society for Heart and Lung Transplantation (ISHLT), IPF represents 2.9% of heart-lung transplants, 29.1% of single LTXs (SLTs) and 14.5% of sequential bilateral lung transplants (BLT) performed in the adult population [6] . Although many obstacles to LTX remain, such as the shortage of donor lungs, opportunistic infection or refractory/fatal allograft rejection and the recurrence of disease in the donor lung, LTX is the ultimate treatment for patients with progressive loss of pulmonary function, especially patients with IPF. In addition, timing for referral is important for a careful optimization of the medical status to decrease the surgical mortality risks and improve outcomes [7] .
The Organ Procurement and Transplantation Network (OPTN) began allocating donor lungs procured in the USA in 1990. The OPTN-directed organ allocation for transplant was determined by waiting time on the transplant list from 1990 to 2005 and did not take into account disease severity or expected benefit [8] . Due to the relative shortage of organs, the growing number of patients on the waiting list, and the increasing number of deaths during the wait for organs, the necessity of a new lung allocation system became increasingly apparent [9] , the use of the lung allocation score (LAS) was implemented in May 2005 by the OPTN. The three main purposes of LAS were: (i) to reduce the number of deaths on the LTX waiting list, (ii) to increase transplant benefit for lung recipients and (iii) to ensure the efficient and equitable allocation of lungs to active LTX candidates [10] . The LAS dramatically changed lung allocation from the previous system that was based solely on accrued time on the waitlist to a new algorithm based on survival probability while on the waitlist combined with the probability of survival to 1 year following transplantation.
Recently, several analyses of the united network of organ sharing (UNOS) database indicated that the LAS significantly reduced waiting time and changed the distribution of diagnoses in LTX recipients [11, 12] . It has become particularly apparent that the proportion of patients with IPF undergoing transplant is increasing as compared with that prior to the implementation of the LAS [6, 11] . We evaluated our institutional outcomes in LTX recipients with ILD over the 15-year time period to assess the impact of the UNOS LAS system on LTX for advanced ILD. We also examined our data for effects on the subset of patients with IPF.
PATIENTS AND METHODS

Donor and recipient characteristics
Between January 1993 and March 2009, a total of 423 LTXs from deceased donors were performed in 405 patients at UWHC. Among these patients, 107 (25.2%) consecutive patients with ILD (IPF, sarcoidosis and other forms of ILD) underwent LTX. Patients transplanted using the LAS (the LAS group, n = 56, May 2005-March 2009) were compared with those transplanted prior to the introduction of the LAS (the pre-LAS group, n = 51, January 1993-April 2005). Patients were offered listing for either SLT or BLT, and nearly all patients with ILD chose this option rather than being listing for bilateral transplant only.
To compare the severity of illness between the groups, the LAS was calculated for the pre-LAS group using the appropriate variables available close to the time of transplantation. Primary graft dysfunction (PGD) was defined and graded according to the ISHLT definition: PaO 2 /FiO 2 <300 and a chest radiograph with a characteristic diffuse infiltrate [13] . Bronchiolitis obliterans syndrome (BOS) was also defined by ISHLT criteria [14] . Patient demographics, donor characteristics, graft function, posttransplant complications and patient and graft survival rates were assessed. This investigation was approved by the University of Wisconsin Human Subjects Committee (approval number M-2009-1308).
Organ procurement and preservation
After median sternotomy, 30 000 units of heparin and 10 mg of phentolamine were given intravenously to prevent vasospasm and to facilitate subsequent organ flushing. Four litres of preservative solution is infused in situ via the main pulmonary artery (PA), and 2 l of retrograde flush through the pulmonary veins. The majority of our donor lungs were perfused with UW solution, but since 2006 the patients received Perfadex® (Vitrolife, Göteborg, Sweden) as preservation solution. The lungs are then stored in the preservation solution at 4°C and returned to our centre.
Peri-operative management
Patients were managed in the intensive care unit (ICU) with standard monitoring including the use of a PA catheter to monitor haemodynamic parameters until stable. Cardiopulmonary bypass (CPB) was instituted peri-operatively if significant haemodynamic instability was encountered during the procedure or if preoperative recipient characteristics suggested that patients would not tolerate the procedure without CPB support. Nitric oxide was administered on a case-by-case basis according to haemodynamic measurements and gas exchange, particularly if significant elevations in PA pressures were observed. All patients were begun on an immunosuppressive regimen of calcineurin inhibitor (cyclosporine or tacrolimus), antimetabolite (azathioprine or mycophenolate) and prednisone.
Post-transplant bronchoscopy and surveillance
All LTX recipients receive surveillance bronchoscopies with bronchoalveolar lavage and transbronchial biopsies (graded according to criteria set by the ISHLT Lung Rejection Study Group) [15] at posttransplant weeks 2, 6, 12, 18, 26, 40 and 52 to detect rejection and/ or infection. Bronchoscopies are also performed whenever necessary for clinical indications with follow-up bronchoscopies performed 4 weeks after a previous bronchoscopy where the acute cellular rejection of any grade was detected. All biopsy results were retrospectively reviewed for this study.
Data acquisition and follow-up
Data were collected prospectively and analysed retrospectively. The LTX database was reviewed for demographic, operative, peri-operative and outcome data. 
Statistical analysis
Categorical data were summarized with frequency distributions and percentages. The mean ± standard deviations were calculated for variables that were normally distributed, and the medians with IQRs were presented for those that were skewed.
Continuous variables were compared by the unpaired t-test or non-parametric Mann-Whitney U-test, whereas nominal variables were compared by means of χ 2 or the Fisher's exact test, as appropriate. The Kaplan-Meier method was used to assess LTX patient survival, lung graft survival and freedom from airway complications and BOS. Log-rank tests were used to assess statistical significance in survival differences between the pre-LAS and LAS groups. A P-value of <0.05 (two-sided) was considered to be statistically significant. All analyses were performed using the SPSS statistical software program (SPSS for Windows version 17.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics are listed in Table 1 . The mean age of recipients was significantly older in the LAS group (P < 0.01). The proportion of diagnoses for ILD was significantly different between the groups (P = 0.04). In particular, the frequency of IPF was higher (64.7% in pre-LAS vs. 82.1% in LAS) in the LAS group. The patients in the LAS group required more pre-transplant supplemental oxygen (3 vs. 5 l/min, P < 0.01) and had lower cardiac index values (3.1 vs. 2.6 l/m 2 , P < 0.01). The estimated LAS was significantly increased from 38.3 in the pre-LAS group to 43.3 in the LAS group (P < 0.01). However, after the implementation of the LAS system, waiting time decreased from 266 to 78 days (P < 0.01). The rate of BLT vs. SLT was lower (35 vs. 16%, P = 0.02), and cold ischaemic time was shorter in the LAS group (434 vs. 299 min, P < 0.01).
Of 107 ILD patients, 79 IPF patients (73.8%) underwent LTX. Characteristics of patients with IPF are listed in Table 2 . The differences between the pre-LAS and LAS groups were similar for the subset of patients with IPF. However, more IPF patients in the LAS group had a history of diabetes or smoking (P = 0.02), and the rate of BLT vs. SLT was not significantly different for pre-LAS vs. LAS (P = 0.06).
Post-operative outcomes for ILD patients are provided in Table 3 . The incidence of PGD, requirement of extracorporeal membrane oxygenation support, reintubation, reoperation and need of dialysis did not differ between the groups. The use of inhaled nitric oxide (iNO) significantly increased in the LAS group (37.3% in pre-LAS vs. 71.4% in LAS, P < 0.01); however, the over 48 h use of iNO was not different between the groups. The length of mechanical ventilation was significantly lower in the LAS group (3.4 vs. 1.2 days, P < 0.01). The length of ICU (8 vs. 4 days, P < 0.01) and hospital stay (24 vs. 11 days, P < 0.01) were significantly decreased in the LAS group. Hospital mortality (11.8 vs. 7.1%, P = 0.51) and the rate of readmission within 30 days after surgery (25.5 vs. 23.2%, P = 0.78) were not different between the two groups. Post-operative outcomes for IPF patients are shown in Table 4 . The differences between the groups were similar to the subset of patients with ILD. The overall survival rate of the LTX recipients with ILD at 1, 3, 5 and 10 years were 81.0, 64.9, 64.9 and 46.3%, respectively. For the pre-LAS group, actuarial survival rates at 1, 3 and 5 years were 82.0, 66.0 and 66.0%, respectively. For the LAS group, actuarial survival rates at 1 and 3 years were 82.5 and 63.0%, respectively. There was no statistical difference in the survival between the groups (log-rank test, P = 0.86, Fig. 1) .
The overall survival rate of the LTX recipients with IPF at 1, 3, 5 and 10 years were 82.3, 63.4, 63.4 and 40.1%, respectively. For the pre-LAS group, actuarial survival rates at 1, 3 and 5 years were 78.8, 63.6 and 63.6%, respectively. For the LAS group, actuarial survival rates at 1 and 3 years were 85.8 and 62.8%, respectively. There was no statistical difference in the survival between the groups (log-rank test, P = 0.98, Fig. 2 ).
DISCUSSION
The LAS system was adopted in the USA to facilitate the allocation of donor lungs to patients at the greatest risk of dying on the waitlist while also seeking to efficiently allocate lungs to active candidates and increase survival probability of candidates who undergo transplantation [10] . Because patients with IPF generally have a poor prognosis and respond poorly to pharmacologic therapies [16] and have been shown to have a significantly increased risk of death while awaiting LTX in the pre-LAS era [17] , patients with IPF as an indication for lung transplant could potentially benefit more than those with other indications with the adoption of the LAS system. Indeed, since the LAS system was adopted, the relative proportion of patients transplanted for the indication of IPF has progressively increased [18] , and IPF has now become the predominant indication for lung transplants performed in the USA. Transplants for other forms of ILD are much less frequently performed, but UNOS data from the pre-LAS era show that patients with other forms of ILD (non-IPF) had a similar risk of dying (with the exception of lymphangioleiomyomatosis) while waitlisted to that of patients with IPF [19] , and patients with non-IPF pulmonary fibrosis may also benefit from the adoption of the US LAS system. IPF is associated with advancing age [3] , and patients with IPF not only tend to be older but frequently have significant comorbid conditions [16] . Additionally, patients with IPF can develop acute exacerbations of their disease that frequently lead to rapid decline in lung function and death [20] . Another potential complication, secondary pulmonary hypertension, frequently occurs as the disease progresses and lung function worsens, and patients with significant pulmonary hypertension have poorer survival than IPF patients without this complication [21] . Patients with IPF and significant pulmonary hypertension are at increased risk for post-transplant complications and poorer survival [22] . Cumulative registry data have indicated that patients with IPF have poorer post-transplant survival than recipients with other major lung transplant indications (e.g. COPD and cystic fibrosis) [23] . The reasons for this difference remain unclear, although these data may be substantially weighted by increased mortality risk for patients with IPF in the early post-transplant period.
Because patients with IPF have generally higher LAS scores [12] and represent an older and more ill patient population with a relatively narrow transplant window due to disease severity and rapidity of disease worsening [24] , the possibility that this patient group may have significantly poorer outcomes with LAS-driven organ allocation is a valid concern. Our data revealed some interesting trends that appeared for our cohort of patients with ILD following the application of the LAS system to our program. Significant increases were observed in age, amount of supplemental oxygen requirement, prevalence of diabetes and prevalence of a history of cigarette smoking, and the post-LAS scores were significantly higher than calculated scores for the pre-LAS cohort. Post-LAS patients also had a significantly lower cardiac index, although there was no significant difference in PA pressures. Time on the waitlist was decreased to one-third of the pre-LAS waitlist time and a significant reduction in cold ischaemia time was observed, but the relative number of patients receiving BLTs significantly declined. These trends were identical to those for the subgroup of IPF recipients only.
Despite the observed increase in LAS scores, amount of supplemental oxygen used, increased use of intra-and peri-operative nitric oxide and significantly lower cardiac index, the post-LAS cohort had significantly decreased time receiving mechanical ventilation and lower ICU and hospital length of stay. Additionally, there was no difference in the post-operative reintubation rate or hospital readmission within 30 days or hospital mortality for pre-LAS vs. post-LAS despite the significantly increased LAS score. Nonetheless, it must be kept in mind that recent advances in medical and surgical management at our institution may contribute to the trends that we observed for the pre-LAS vs. post-LAS cohorts, and the shorter length of stay for the post-LAS group may reflect the relative increase in the number of recipients who received SLTs after the LAS implementation. Our cohort was not large enough to examine the effect of relative LAS score values on the post-transplant outcome and survival, but data are emerging that higher LAS scores correlate with significantly worse posttransplant survival for patients with IPF [25] .
We have made gradual changes in the medical management of our recipients over the past two decades that consisted of (i) the gradual introduction of tacrolimus and mycophenolate in place of cyclosporine and azathioprine, respectively, (ii) the adoption of a prophylactic regimen to prevent CMV infection, (iii) prophylaxis to prevent aspergillosis and (iv) administration of azithromycin to patients displaying evidence of declining allograft function. Other recent changes include (i) improved surgical management including operative technique and lung preservation, (ii) ensuring direct attending level post-operative management in the ICU and (iii) the gradual formation of a large, multidisciplinary group of healthcare professionals who are directly involved in all aspects of the pre-and post-transplant care of these patients. These changes may indeed have had an impact on our observations and may account for the lack of a worsening trend in post-transplant outcomes, despite the transition to the LAS system and prioritizing transplantation for more severely ill waitlisted patients. However, it would be exceedingly difficult to assess or quantitate the impact of such changes on the outcomes of our recipient cohorts with ILD. Additionally, the lack of improvement in long-term survival rates for the post-LAS recipient cohorts, despite improvements in recipient management that have occurred over time may be due to the tendency to transplant a sicker cohort of patients since the adoption of the LAS (as suggested by the higher LAS scores for this group).
Our findings support preliminary trends observed by other centres as well as analyses of national data that the adoption of the LAS system has been associated with decreased time on the waitlist for lung transplant candidates with ILD and the subset of those with IPF without being associated with a negative impact on posttransplant survival despite the increased age and disease severity (as reflected in the significantly higher LAS score) for patients with ILD. Our data support a benefit of the LAS for IPF patients by reducing waitlist time and facilitating organ allocation. Until effective non-transplant therapies can be discovered and implemented for patients with IPF as well as the other forms of fibrotic ILD that progress despite immunosuppressive and anti-inflammatory therapies, LTX remains the best option for the improved quality of life and survival for patients with advanced forms of ILD. However, the additional examination of the correlation of short-and long-term outcomes with LAS scores is needed to determine if a threshold can be identified for patients with fibrotic lung disease that identifies excessive risk for poor outcome that precludes proceeding with LTX for a defined subset of these candidates. 
